Amicus Therapeutics, Inc. (FOLD) News
Filter FOLD News Items
FOLD News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
FOLD News Highlights
- FOLD's 30 day story count now stands at 6.
- Over the past 19 days, the trend for FOLD's stories per day has been choppy and unclear. It has oscillated between 1 and 3.
- The most mentioned tickers in articles about FOLD are SMID, STEP and BIO.
Latest FOLD News From Around the Web
Below are the latest news stories about AMICUS THERAPEUTICS INC that investors may wish to consider to help them evaluate FOLD as an investment opportunity.
‘Time to Pull the Trigger,’ Says Morgan Stanley About These 2 Healthcare StocksIt’s been a bountiful year for the stock market but that doesn’t mean there haven’t been laggards. The biotech industry, for example, has underperformed. While the Nasdaq Biotechnology Index (NBI) shows a 3% year-to-date gain, that is still some distance below the S&P 500’s 24% return. Therefore, with investor sentiment subdued, and some SMID-cap biotech firms still needing to raise capital against a challenging capital markets backdrop, Morgan Stanley’s Jeffrey Hung says the setup for SMID-cap |
Amicus Therapeutics Inc's Chief Development Officer Sells SharesOn December 20, 2023, Jeff Castelli, Chief Development Officer of Amicus Therapeutics Inc (NASDAQ:FOLD), sold 19,154 shares of the company, according to a recent SEC Filing. |
Why Is Amicus Therapeutics (FOLD) Up 15% Since Last Earnings Report?Amicus Therapeutics (FOLD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues. |
BIO names longtime Amicus head John Crowley as new CEOCrowley, a rare disease advocate who led Amicus for nearly two decades, will take the reins as the industry group seeks to challenge Medicare’s new drug pricing powers. |
Amicus Therapeutics Congratulates Executive Chairman John F. Crowley on Appointment as Next President and CEO of BIOCrowley to Step Down from Amicus Board of Directors in March 2024 and Become Amicus Chairman Emeritus Michael Raab, Current Lead Independent Director, to Become Chairman of Amicus Board of Directors PRINCETON, N.J., Dec. 05, 2023 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that John F. Crowley, Executive Chairman of Amicus Therapeutics, will step down from the Amicus Board of Directors and assume the role of President and Chief Executive Officer of BIO, the Biotechnolo |
He Designed Drugs to Save His Children. Now He’s Working to Save Biotech, Too.John Crowley will become a top lobbyist for the industry as it confronts investor skepticism and regulatory challenges. |
7 Stocks Most Likely to Follow in WeWork’s Woeful FootstepsThese troubled stocks to sell look even worse following WeWork's bankruptcy and will only hurt holders the longer they hold on. |
Amicus Therapeutics, Inc. (NASDAQ:FOLD): Are Analysts Optimistic?We feel now is a pretty good time to analyse Amicus Therapeutics, Inc.'s ( NASDAQ:FOLD ) business as it appears the... |
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Q3 2023 Earnings Call TranscriptAmicus Therapeutics, Inc. (NASDAQ:FOLD) Q3 2023 Earnings Call Transcript November 8, 2023 Amicus Therapeutics, Inc. beats earnings expectations. Reported EPS is $-0.07, expectations were $-0.08. Operator: Good morning, ladies and gentlemen and welcome to the Amicus Therapeutics Third Quarter 2023 Financial Results Conference Call and webcast. [Operator Instructions] As a reminder, this conference is being […] |
Amicus' (FOLD) Q3 Loss Narrows, Galafold Sales View UpdatedAmicus (FOLD) incurs a narrower-than-expected loss in the third quarter. However, revenues beat estimates. The company tightens Galafold revenue guidance for 2023. |